Tycel Jovelle Phillips, MD, University of Michigan

Articles by Tycel Jovelle Phillips, MD, University of Michigan

Lenalidomide and Bortezomib for Mantle Cell Lymphoma

ByJohn P. Leonard, MD, New York-Presbyterian/Weill Cornell Medicine,Krish Patel, MD, Swedish Medical Center,Tycel Jovelle Phillips, MD, University of Michigan,Andrew D. Zelenetz, MD, PhD, Memorial Sloan Kettering Cancer Center

January 26th 2021

Go-To Treatment Regimens in Mantle Cell Lymphoma

ByJohn P. Leonard, MD, New York-Presbyterian/Weill Cornell Medicine,Krish Patel, MD, Swedish Medical Center,Tycel Jovelle Phillips, MD, University of Michigan,Andrew D. Zelenetz, MD, PhD, Memorial Sloan Kettering Cancer Center

January 26th 2021

Treatment Approaches in Mantle Cell Lymphoma

ByJohn P. Leonard, MD, New York-Presbyterian/Weill Cornell Medicine,Krish Patel, MD, Swedish Medical Center,Tycel Jovelle Phillips, MD, University of Michigan,Andrew D. Zelenetz, MD, PhD, Memorial Sloan Kettering Cancer Center

January 19th 2021

Accurately Diagnosing Mantle Cell Lymphoma

ByJohn P. Leonard, MD, New York-Presbyterian/Weill Cornell Medicine,Krish Patel, MD, Swedish Medical Center,Tycel Jovelle Phillips, MD, University of Michigan,Andrew D. Zelenetz, MD, PhD, Memorial Sloan Kettering Cancer Center

January 19th 2021

Trending on OncLive

FDA Approves Tucatinib Plus Trastuzumab/Pertuzumab as First-Line Maintenance in Advanced HER2+ Breast Cancer

FDA Grants Breakthrough Therapy Designation to Telisotuzumab Adizutecan Plus Bevacizumab in Refractory mCRC

FDA Grants Breakthrough Therapy Designation to Temab-A in Previously Treated c-Met–Expressing Nonsquamous NSCLC

September Roundup of FDA Approvals in Oncology: 8 Decisions to Know

Meta-Analysis Shows Ropeginterferon Alfa-2b Benefit Over Phlebotomy, but Not Hydroxyurea, in Polycythemia Vera